Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Damage Not Controlled

Executive Summary

As financial turmoil broke out around the world in the wake of the vote for Brexit, UK pharma majors GlaxoSmithKline and AstraZeneca saw their stock rise. There's an uncertain outlook for the broader life sciences sector.

You may also be interested in...



Stockwatch: Pandora’s Interim Analysis

The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?

Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop

The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.

Antisoma backs pipeline to get through ASA404 disaster

Antisoma is determined to bounce back from the recent catastrophic disappointment with its lead anticancer candidate ASA404 and is hoping clinical data expected over the coming year from other product candidates will turn its fortunes around.

Topics

Related Companies

UsernamePublicRestriction

Register

SC065519

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel